<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03846349</url>
  </required_header>
  <id_info>
    <org_study_id>UAW strenghtening in OSAS</org_study_id>
    <nct_id>NCT03846349</nct_id>
  </id_info>
  <brief_title>Reinforcement of Upper Airway Muscles in Patients With OSAS</brief_title>
  <official_title>Non-invasive Reinforcement of the Upper Airway Dilator Muscles as an Alternative Approach to Treat Patients With Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haute Ecole de Santé Vaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haute Ecole de Santé Vaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effectiveness of a simple and quick myofunctional reeducation
      protocol of the tongue in reducing the obstructive sleep apnea syndrome (OSAS) severity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled study. Participants with moderate OSAS severity will be
      either allocated to receive a myofunctional reeducation protocol (study group) or a sham
      protocol (control group). Apnea-hypopnea index (AHI) will be measured before and at the end
      (6 weeks) of the protocol. Participants from the study group will follow an upper airway
      reinforcement regimen using the IOPI (Iowa Oral Performance Instrument) device over 6 weeks
      while participants from the control group will perform a sham reeducation protocol using an
      &quot;EMT threshold&quot; at minimal resistance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in AHI (apnea-hypopnea index) on polygraphy</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Evolution of the number of apnea-hypopnea events (AHI) over 6 weeks. The AHI value at discharge will be compared with the baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tongue strength using the IOPI device</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Evolution of tongue strength over 6 weeks. Tongue strength will be measured by asking the participants to squeeze the tongue bulb of IOPI as much as possible over 3 seconds. Three trials are accepted and the best value will be recorded (Pmax). Pmax at discharge will be compared with Pmax at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tongue endurance using the IOPI device</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Evolution of tongue endurance over 6 weeks. Tongue endurance will be measured by asking the participants to sustain a tongue pressure against the IOPI bulb at 50% of Pmax. Endurance will be assessed by measuring the holding duration of 50% of Pmax. Holding duration at discharge will be compared with the value at baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from the study group will follow an upper airway reinforcement regimen using the IOPI device over 6 weeks. The reinforcement protocol will be adapted each week to improve Percentage of initial strength Exercises will be adapted each week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants from the control group will perform a sham reeducation protocol using an &quot;EMT threshold&quot; at minimal resistance. The expiratory pressure will remain unchanged over the weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IOPI</intervention_name>
    <description>IOPI is a portable device with a tongue bulb used to reinforce upper airway muscles.</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EMT threshold</intervention_name>
    <description>EMT threshold is a small portable device producing a positive expiratory pressure when the patient is exhaling.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate obstructive sleep apnea syndrome (AHI between 15 and 30 events per hour)

          -  Poor adherence to continuous positive airway pressure (&lt; 4h per night)

        Exclusion Criteria:

          -  Craniofacial malformation

          -  Use of hypnotic medication

          -  Had stroke in the past

          -  Present a concurrent neuromuscular or severe obstructive nasal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier Contal, PhD</last_name>
    <phone>+41213168122</phone>
    <email>olivier.contal@hesav.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>William Poncin, PhD</last_name>
    <email>william.poncin@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ligue Pulmonaire Genevoise</name>
      <address>
        <city>Genève</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Contal, PhD</last_name>
      <phone>+41213168122</phone>
      <email>olivier.contal@hesav.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haute Ecole de Santé Vaud (HESAV)</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Contal, PhD</last_name>
      <phone>+41213168122</phone>
      <email>olivier.contal@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>William Poncin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Haute Ecole de Santé Vaud</investigator_affiliation>
    <investigator_full_name>Olivier Contal</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

